Price (delayed)
$57.66
Market cap
$2.88B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$2.65B
Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers
There are no recent dividends present for AXNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.